Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in pediatric Crohn's disease
2022-000811-29Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in Crohn's disease comparing Mirikizumab with Placebo (2 arms). Primary endpoint: Percentage of participants with clinical response by Pediatric Crohn's Disease Activity Index and endoscopic response by Simple Endoscopic Score for Crohn's Disease. Started Nov 2022; status: active.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2022-000811-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000811-29.